Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy
Authors:
- Birgit GrundBGBirgit Grund
- Steven G. DeeksSDSteven G. Deeks
- James D. NeatonJNJames D. Neaton
- INSIGHT SMART/ESPRIT/SILCAAT Study GroupIGINSIGHT SMART/ESPRIT/SILCAAT Study Group
Open Access
- 12 May 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0155100
Abstract
Despite effective antiretroviral treatment (ART), HIV-positive individuals are at increased risk of serious non-AIDS conditions (cardiovascular, liver and renal disease, and cancers), perhaps due in part to ongoing inflammation and/or coagulation. To estimate the potential risk reduction in serious non-AIDS conditions or death from any cause that might be achieved with treatments that reduce inflammation and/or coagulation, we examined associations of interleukin-6 (IL-6), D-dimer, and high-sensitivity C-reactive protein (hsCRP) levels with serious non-AIDS conditions or death in 3 large cohorts. In HIV-positive adults on suppressive ART, associations of IL-6, D-dimer, and hsCRP levels at study entry with serious non-AIDS conditions or death were studied using Cox regression. Hazard ratios (HR) adjusted for age, gender, study, and regression dilution bias (due to within-person biomarker variability) were used to predict risk reductions in serious non-AIDS conditions or death associated with lower “usual” levels of IL-6 and D-dimer. Over 4.9 years of mean follow-up, 260 of the 3766 participants experienced serious non-AIDS conditions or death. IL-6, D-dimer and hsCRP were each individually associated with risk of serious non-AIDS conditions or death, HR = 1.45 (95% CI: 1.30 to 1.63), 1.28 (95% CI: 1.14 to 1.44), and 1.17 (95% CI: 1.09 to 1.26) per 2x higher biomarker levels, respectively. In joint models, IL-6 and D-dimer were independently associated with serious non-AIDS conditions or death, with consistent results across the 3 cohorts and across serious non-AIDS event types. The association of IL-6 and D-dimer with serious non-AIDS conditions or death was graded and persisted throughout follow-up. For 25% lower “usual” IL-6 and D-dimer levels, the joint biomarker model estimates a 37% reduction (95% CI: 28 to 46%) in the risk of serious non-AIDS conditions or death if the relationship is causal. Both IL-6 and D-dimer are independently associated with serious non-AIDS conditions or death among HIV-positive adults with suppressed virus. This suggests that treatments that reduce IL-6 and D-dimer levels might substantially decrease morbidity and mortality in patients on suppressive ART. Clinical trials are needed to test this hypothesis.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (U01-AI068641)
- National Institute of Allergy and Infectious Diseases (US) (U01-AI046362)
- National Institute of Allergy and Infectious Diseases (US) (U01-AI042170)
- National Institute of Allergy and Infectious Diseases (US) (U01-AI46957)
- National Institute of Allergy and Infectious Diseases (3U 01-AI068641-0451)
- National Institute of Allergy and Infectious Diseases (US) (3U01-AI06841-0551)
This publication has 41 references indexed in Scilit:
- Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study CohortJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patientsAIDS, 2010
- Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV InfectionThe Journal of Infectious Diseases, 2010
- Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort StudiesClinical Infectious Diseases, 2010
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisThe Lancet, 2010
- Interleukin-2 Therapy in Patients with HIV InfectionNew England Journal of Medicine, 2009
- Association of C-Reactive Protein and HIV Infection With Acute Myocardial InfarctionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Associations of factor VIIIc, D‐dimer, and plasmin–antiplasmin with incident cardiovascular disease and all‐cause mortalityAmerican Journal of Hematology, 2009
- Inflammation, Hemostasis, and the Risk of Kidney Function Decline in the Atherosclerosis Risk in Communities (ARIC) StudyAmerican Journal of Kidney Diseases, 2009